Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase II PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma

Avalo Therapeutics, Inc. announced that it completed enrollment of the 80 patients targeted for the Phase II PEAK Trial evaluating AVTX-002 in patients with non-eosinophilic asthma.